Inspirna to Present at the Jefferies Healthcare Conference

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 26, 2024

Webber Marketing Celebrates the 10th Anniversary of the National Battle of the Bands with Exclusive Film Releases on YouTube • Gopuff Invites the World to "Bring The Magic" to Everyday Experiences with the Launch of Its Largest-Ever Brand Campaign • Coastal Carolina, Southwestern Law School, and Other Institutions Streamline Accessibility Workflows With YuJa's PDF Remediation • Cosmetic Executive Women (CEW) Hosts Achiever Awards • In Support of PEPSI® x Mary J. Blige Strength of a Woman Partnership, The Brand Launches $100,000 Fund to Support Yonkers Wo • ADS-TEC Energy (ADSE) to Host Business Update Call on April 30th Following the Release of Full-Year 2023 Results • FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV • Manulife Investment Management Announces Forest Climate Fund's Second Close Bringing Total Commitments Up to $334.5 Million • Rooter Hero Plumbing & Air's employees host clothing drive for Hope the Mission shelters • C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer&rs • Aspen Technology Introduces New Strategic Planning for Sustainability Pathways Solution • PPG again earns EcoVadis gold rating for sustainability practices, ranks among top 7% of evaluated companies • Nonprofits from Inception Fertility and Caden Lane Team Up to Expand Financial Accessibility to Fertility Care • McCain Foods Plants 18,000 Trees in Wisconsin, Fulfilling 2022 Promise to Plover Community • BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report • Dual Enrollment Helps High School Students Launch Rewarding Careers • New Report: Employers Play Critical Role in Curbing Today's Youth Mental Health Crisis • FOSUN FOR GOOD, CREATING IMPACT: Fosun International Issued its 2023 ESG Report and the Second Climate Information Disclosures R • Operation HOPE and SBA Forge Strategic Alliance to Empower Small Businesses Across America • Cross River, Financially CLEAN and Visa Host Financial Literacy Event for NYC Students at the New York Stock Exchange

Inspirna to Present at the Jefferies Healthcare Conference

NEW YORK , June 01 /Businesswire/ - Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today that Chief Executive Officer Dr. Usman “Oz” Azam, M.D., will participate in a corporate presentation at the Jefferies Healthcare Conference on June 8, 2023 at 1:30pm ET.

Links to the live and archived versions of the presentation will be available on Inspirna’s website under the News section.

About Inspirna

Inspirna, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. The company is pursuing several first-in-class drug candidates. Inspirna’s lead drug candidate, ompenaclid (RGX-202), is an orally-administered small molecule that targets the CKB/SLC6A8 pathway. This pathway becomes activated in the tumors of select patients where it enables the generation of the energy molecule ATP in response to tumor hypoxia. Ompenaclid is currently being tested in a Phase 1b/2 clinical trial in combination with standard-of-care FOLFIRI and bevacizumab for the second line treatment of patients with advanced or metastatic RAS mutant colorectal cancer.

Inspirna’s second clinical stage drug candidate, abequolixron (RGX-104), is an oral small molecule activator of LXR/APOE that inhibits angiogenesis and tumor myeloid derived suppressor cells to enhance the immune response against tumors. Abequolixron is currently being tested in a Phase 1b/2 clinical trial in patients with advanced or metastatic lung cancer in combination with docetaxel and endometrial cancer in combination with ipilimumab through a clinical collaboration with Bristol Myers Squibb.

Inspirna identifies novel cancer targets using its microRNA-based target discovery platform, RNA-DRIVEr, which was originally developed by Inspirna’s scientific co-founders at The Rockefeller University and exclusively licensed to Inspirna. The Company brings together distinguished scientific founders, a seasoned board of directors, and a leadership team comprised of experienced drug developers. The Company is funded by leading biotechnology investors, including Novo Holdings A/S, Sofinnova Partners, Sands Capital, Vivo Capital, Lepu Holdings Limited, Sixty Degree Capital, Silicon Valley Bank, K2 HealthVentures, Oceanpine Capital, WuXi PharmaTech Healthcare Fund I, LP, Alexandria Venture Investments, LLC, Dreavent 6, Exor Seeds, and the Partnership Fund for New York City. For more information, please visit https://inspirna.com/.